Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646366 | 0.83 | CYP2A6 (0.38) | HSP90AA1MEN1KMT2ARAB9ACYP2A6 | |
| SCHEMBL3125932 | 0.77 | HSP90AA1 (0.55) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL5336284 | 0.77 | CYP2A6 (0.41) | LMNAMEN1KMT2ARAB9ACYP2A6 | |
| SCHEMBL4168284 | 0.76 | EPM2A (0.39) | HSP90AA1LMNAMEN1KMT2ACYP2A6 | |
| SCHEMBL21326404 | 0.76 | HSP90AA1 (0.53) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL13654389 | 0.74 | BACE1 (0.53) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL13737297 | 0.74 | HSP90AA1 (0.56) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL1744396 | 0.74 | HSP90AA1 (0.52) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL2090846 | 0.74 | HSP90AA1 (0.52) | HSP90AA1LMNAMEN1KMT2ARAB9A | |
| SCHEMBL13907589 | 0.74 | HSP90AA1 (0.47) | HSP90AA1LMNAMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022015624-A1 | SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR | SCHRÖDINGER, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20190071450-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA (CH) | 2019-03-07 | — | — | US | disclosed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-9029399-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-05-12 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | O'CONNOR STEPHEN P (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1358178-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | Bristol-Myers Squibb Company (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6555542-B1 | Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
| WO-2002060894-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071450-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | SNCA, PARK7, NLN | HSP90AA1 1973/4885LMNA 314/4885MEN1 3649/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | HSP90AA1 711/4885LMNA 1297/4885MEN1 2651/4885 |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | STS, SULT1E1, F8 | HSP90AA1 2498/4885LMNA 2015/4885MEN1 3235/4885 |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | HSP90AA1 2777/4885LMNA 4390/4885MEN1 1136/4885 |
| US-20140228386-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | HSP90AA1 2777/4885LMNA 4390/4885MEN1 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.